



1 Article

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

2 Chemically-Gated and Sustained Molecular

3 Transport through Nanoporous Gold Thin Films in

4 Biofouling Conditions

- 5 Barath Palanisamy ¹, Noah Goshi ¹ and Erkin Seker ^{2,*}
- Department of Biomedical Engineering University of California, Davis, Davis, CA 95616, USA;
 bpalanisamy@ucdavis.edu; nkgoshi@ucdavis.edu
- Department of Electrical and Computer Engineering University of California, Davis, Davis, CA 95616,
 USA; eseker@ucdavis.edu
- * Correspondence: eseker@ucdavis.edu; Tel.: +1 530-752-7300
- 11 Received: date; Accepted: date; Published: date

Abstract: Sustained release and replenishment of the drug depot are essential for the long-term functionality of implantable drug-delivery devices. This study demonstrates the use nanoporous gold (np-Au) thin films for in-plane transport of fluorescein (a small-molecule drug surrogate) over large (mm-scale) distances from a distal reservoir to the site of delivery, thereby establishing a constant flux of molecular release. In the absence of halides, the fluorescein transport is negligible due to a strong non-specific interaction of fluorescein with the pore walls. However, in the presence of physiologically-relevant concentration of ions, halides preferentially adsorb onto the gold surface, minimizing the fluorescein-gold interactions and thus enabling in-plane fluorescein transport. In addition, the nanoporous film serves as an intrinsic size-exclusion matrix and allows for sustained release in biofouling conditions (dilute serum). The molecular release is reproducibly controlled by gating it in response to the presence of halides at the reservoir (source) and the release site (sink) without external triggers (e.g., electrical, mechanical).

Keywords: drug delivery; stimulus-responsive; nanoporous gold; sustained release; biofouling

1. Introduction

Implantable drug delivery platforms are emerging as powerful technologies for treating and managing a wide range of medical conditions, including cancer, diabetes, and epilepsy [1-7]. These drug delivery modalities have shown promise in overcoming several pharmaceutical challenges by improving permeation across the blood-brain barrier [8], reducing systemic side effects through targeted delivery at the site of interest [9], and maintaining the delivery dose within the therapeutic window for high efficacy and low toxicity [10]. One class of drug delivery technology is based on the use of macro-scale infusion pumps or miniaturized microelectromechanical systems (MEMS)-based pumps, where the delivery segment (e.g., cannula) and the reservoir can be both implanted [11–13]. In both cases, the pharmaceuticals are delivered in a liquid vehicle solution by convective means, which leads to the problem of potentially-damaging increase of local pressure in the target tissue. Ideally, only the pharmaceutical molecules should be delivered into the tissue, which requires a nonconvective transport mechanism. To that end, non-degrading nanostructured materials (e.g., porous anodic alumina [14], carbon nanotubes [15,16], and porous silicon [1,17]) and degrading polymers [18,19] have shown promise for molecular release of the pharmaceuticals without volume or pressure change at the delivery site. However, there are still obstacles, such as biofouling of the nanostructured material, controlling the release rate, and the unavoidable depletion of drug molecules in a fullyimplanted system. While there have been some remedies (e.g., anti-biofouling coatings [20] and sizeexclusion membranes [21]) and stimulus-responsive gating mechanisms [22-25] for the former two

obstacles, the latter has remained non-trivial, especially for non-convective drug delivery platforms. There have been creative solutions, such as replenishment of drug depot via selective capture of pharmaceuticals at the delivery site [26]. However, these solutions still have shortcomings such as their applicability to anatomical sites with reduced transport from the blood (e.g., central nervous system).

Taken together, implantable drug delivery platforms that rely on non-convective transport require the ability to (i) sustain pharmaceutical release, (ii) allow for pharmaceutical replenishment at a location distal to the delivery site, (ii) maintain functionality in biofouling conditions, and (iii) regulate release rate in response to external and internal stimuli. In this paper, we use nanoporous gold (np-Au) to address these challenges. Np-Au is fabricated through the dissolution of silver from silver-rich gold-silver alloy where surface diffusion of gold at the metal-electrolyte interface creates a bicontinuous open-pore structure [27]. The morphology can be tuned by post-processing techniques (e.g., thermal [28–30], electrical [31], electrochemical [32], photo-thermal [33,34]) to yield np-Au with ligament and pore diameters spanning several orders of magnitudes (10-1000s nm) with self-similar morphologies [28,35]. In addition to the tunable morphology, np-Au exhibits other desirable features such as high surface area to volume ratio [36], electrical conductivity [37], biocompatibility [38], biofouling resilience [39], compatibility with conventional microfabrication processes [40,41], and facile surface functionalization via gold-thiol chemistry [42]. These benefits make np-Au an attractive material system for drug delivery [43], short nucleic acid detection [44], and catalysis [45,46]. Here, we report a computational and experimental study of in-plane molecular transport in np-Au thin films integrated into a microfluidic model of a reservoir distal to the pharmaceutical delivery site. The study demonstrates sustained (via replenishment of molecules at the distal reservoir) and controllable (via gating with physiologically-relevant solutions) molecular release in biofouling conditions (dilute fetal bovine serum).

2. Materials and Methods

2.1. Fabrication and Characterization of np-Au Thin Films

Np-Au thin films were fabricated as previously described [47]. Briefly, a stencil mask was used to pattern np-Au and pl-Au thin films on piranha-cleaned glass coverslips (**Figure 1**a). For np-Au, Au_{0.36}Ag_{0.64} (atomic %) alloy was deposited on top of Cr adhesion layer (160 nm-thick) and Au seed layer (80 nm-thick) via sputter-deposition. In order to fabricate different thicknesses of np-Au thin films, the sputter-deposition time of the alloy was varied (10 min for 500 nm-nominal thickness for np-Au, 5 min for 250 nm nominal thickness for t-np-Au). The alloy-coated coverslips were then dealloyed in nitric acid (70%) at 55 °C for 15 min to produce the *as dealloyed* np-Au film. To obtain the coarser morphology (A-np-Au), a subset of the np-Au thin films were thermally treated on a hotplate at 250 °C for 40 seconds. Planar gold (pl-Au) films were fabricated by sputtering only Au (10 min) over the Cr adhesion layer with no dealloying step. Scanning electron microscopy (SEM) was used to obtain high-resolution images of top and side views of each np-Au thin film type at 100,000x magnification (FEI Nova Nano-SEM430, Phenom World, Hillsboro, OR, USA). ImageJ was used to analyze each film's thickness and surface pore coverage using previously described methods [47].

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

Figure 1. (a) Fabrication schematic of the in-plane transport device. (b) A 3D rendering of the devices illustrating the fully fabricated device along with the four cloning cylinders on top of the PDMS manifold. (c) Overhead view of the in-plane transport device, with 100 μ M of sodium fluorescein in the source reservoir and the matching vehicle solution in the sink reservoir.

2.2. Transport Characterization

The construction of the in-plane transport device followed standard microfluidic and soft lithography techniques. Using photolithography, a silicon wafer mold with SU-8 (75 µm-thick) features with a source reservoir and a sink reservoir was fabricated. A 10:1 mass ratio of elastomer base and curing agent (Dow Corning, Midland, MI, USA) was mixed and poured onto the mold. After removing the air bubbles under vacuum, the mold and elastomer mixture were cured at 80 °C for 2 hours to cross-link the polymer. A biopsy punch was used to open holes at the corners of each reservoirs, and cloning cylinders (Sigma-Aldrich, St. Louis, MO, USA) were fixed over the opening using additional PDMS (Figure 1b). The PDMS manifold was permanently bonded over the np-Au or Au patterned thin-film coverslips following treatment with air-plasma at 10 W for 30 sec (Harrick Plasma PDC-32G, NY, USA). Depending on the experimental condition, 150 µL of either DI water or Dulbecco's Phosphate Buffered Saline with MgCl₂ (0.1 g L⁻¹) and CaCl₂ (0.133 g L⁻¹) (PBS) was added to each device's four cloning cylinders to ensure hydrophilicity and wicking of the solution throughout the thin films. For the devices in the DI water condition, the source reservoir was replaced with 100 µM of sodium fluorescein (Sigma-Aldrich, St. Louis, MO, USA) dissolved in DI water, while for the PBS conditions the source reservoir was replaced with 100 µM fluorescein dissolved in PBS. A top view of this device illustrates the fluorescein solution in the source reservoir and vehicle solution in the sink reservoir (Figure 1c). To quantify the amount of fluorescein accumulating in the sink reservoir, samples (10 µL) from each cloning cylinders on the sink side were sampled every 12 h for 3 days. Following sampling, the same volume of vehicle solution was added maintain the liquid volume in the sink reservoir. Prior to using a fluorospectrometer (Nanodrop ND-3300, Thermo Fisher Scientific, Waltham, MA, USA) to obtain the fluorescence intensity attributed to fluorescein (emission λ = 515 nm), NaOH (10 μ L, 50 mM) was added to each sample to ensure maximum fluorescence. The cumulate release of fluorescein with respect to release duration was obtained by fluorometric quantification of the samples. To verify the experimental results, COMSOL Multiphysics® 5.5 was used to obtain a two-dimensional numerical solution for in-plane transport using the Species Transport in Porous Media module. The geometry was constructed via three tangent rectangles each having a length of 1 mm and height as the thickness for each film (Figure S2a). Left edges and right edges were constrained to 100 μM and 0 μM , respectively. We assumed that at t = 0, initial concentration in the film was 0. We computed solutions from 0 to 3 days with hourly increments. To calculate the total mass of fluorescein released into the sink reservoir, we solved for the flux at x = 2

mm, multiplied it by the cross-sectional area of the thin film normal to the molecular transport direction, and integrated it with respect to time. Cross sectional area was calculated via multiplying film thickness and width (5 mm). For the DI water condition, where Langmuir isotherm model was used to simulate adsorption phenomenon, we performed through-thickness release experiments (as described previously [43]) to obtain the Langmuir isotherm constant (K_{eq}) and maximum available adsorption sites (Q_{max}), as shown in **Figure S1**.

2.3. Biofouling Resilience

To determine the influence of biofouling medium on the transport of fluorescein ions, we repeated the in-plane transport experiments described earlier; however, the source reservoir was filled with 100 μ M of sodium fluorescein in PBS and the sink reservoir was filled with either FBS (10%) in PBS or only PBS as the control. The fluorescein concentration in the sink reservoir was quantified every 12 hours for 6 days. To account for evaporation, 3 μ L of DI was added to each cloning cylinder at each sampling time point and the evaporation/volume additions were taken into account for the concentration calculations.

2.4. Chemical Gating

For the gating experiments, we alternated either the source or sink reservoir content with DI water or PBS. For source gating, we switched the source reservoir content from fluorescein in DI water (Fluo+DI) to fluorescein in PBS (Fluo+PBS) while maintain sink in DI water. For sink gating, we switched the sink reservoir content from DI water to PBS while maintaining the source reservoir with Fluo+DI. 3 μ L of DI water was added to each cloning cylinder to account for evaporation effects. At the time of switching the reservoir contents, the liquid of interest was completed removed and washed three times with DI water. Next, the alternate solution was added to the empty cloning cylinders. The fluorescein concentration in sink reservoir was evaluated every 12 hours for 20 days. Since replacing the sink reservoir content removed the fluorescein molecules (resetting the concentration to zero), we only displayed the cumulative release for clarity.

2.5. Statistical Analysis

For each experiment, a minimum of three replicates (n = 3) was used. For statistical comparison of multiple groups, one-way ANOVA followed by *post-hoc* Tukey test was used to compare each film's morphology, thickness, and transport rates in various gating scenarios (sink gating vs. source gating). A two-tailed Student's t-test assuming unequal variances was performed to compare transport rates in biofouling conditions. For all experiments, the statistical significance was determined at p < 0.05.

3. Results and Discussion

3.1. Nanoporous Gold Thin Film Properties

We fabricated three types of np-Au thin-film samples by varying the film thickness and pore morphology: np-Au (500 nm nominal thickness; original morphology), annealed np-Au (A-np-Au; 500 nm nominal thickness; coarsened morphology), and thin np-Au (t-np-Au; 250 nm nominal thickness; original morphology). The np-Au films were produced by successive sputter-deposition of a chrome adhesion layer, gold seed layer, and gold-silver precursor alloy, followed by its subsequent dealloying in nitric acid to obtain a bicontinuous open-pore structure, as outlined in **Figure 1a**. **Figure 2** shows the top view and cross-section of the resulting np-Au films and the corresponding thicknesses, volumetric porosity, and surface pore coverage. Thermal treatment enhances surface diffusion of gold and leads to the coarser pore morphology in A-np-Au [28]. During this process, the substrate prevents planar contraction and as a result decreases the thickness by 11.7% [48]. The volumetric porosity (void percentage) of np-Au is primarily based on the initial alloy composition, where the porosity is reduced due to the film shrinkage during dealloying, resulting in

a porosity of ~55% for both the regular np-Au and the thinner t-np-Au, as described previous [43]. For the A-np-Au sample, the volumetric porosity was reduced to 49% due to film shrinkage during thermal annealing (**Table S1**). There was no statistically-significant difference (p value = 0.57) in the surface pore coverage (obtained by image processing) for the two np-Au films of different thicknesses (495 ± 4 nm and 256 ± 9 nm, respectively) in agreement with previous studies [41,43]. The repeatable fabrication approach for creating np-Au thin films with varying thickness and morphology allows for carrying out the systematic studies of molecular transport described next.




Figure 2. Top- and side-view scanning electron microscope images of various thicknesses and morphologies of gold thin films. The A-np-Au film exhibits a coarser morphology and 11.7% reduction in thickness. The t-np-Au films exhibits similar morphology as np-Au, but with halved thickness. Scale bar applies to all images (mean \pm standard deviation, n = 3).

3.2. In-Plane Fluorescein Transport

As stated earlier, a major obstacle in implantable drug delivery systems is the need to replenish the drug depot for continuous device functionality [49]. Common nanoporous materials for drug delivery, such as porous anodic alumina [14,50] or track-etched membranes [51,52] have columnar pores without lateral connectivity. In contrast, np-Au thin films have lateral pore connectivity that should allow for in-plane molecular transport over significant distances [53], such as between a refillable, distal drug reservoir and the actual site of drug release (**Figure 1**c). Here, we investigate this functionality, particularly with a focus on the influence of film properties and ionic strength at the reservoir and release sites.

We first investigated in-plane transport of fluorescein ions through np-Au thin films under different ionic environments. Fluorescein is a common surrogate for small-molecule drugs, such as cytosine arabinoside (Ara-C) [54], and its intrinsic fluorescence allows for easy characterization via fluorometric methods. As a model test system to represent a distal reservoir (source) and drug release site (sink) connected via a np-Au thin film, we fabricated polydimethylsiloxane (PDMS) chambers by soft lithography and permanently bonded the PDMS manifold over the np-Au thin-film test structures (**Figure 1**a,b). The source reservoir was filled with 100 µM sodium fluorescein in either deionized (DI) water or Dulbecco's Phosphate Buffered Saline with MgCl₂ (0.10 g L-1) and CaCl₂ (0.13 g L-1) (PBS) and the matching vehicle solution (DI water or PBS) was added to the sink reservoir (**Figure 1**c). The sink reservoirs were sampled every 12 h for three days and evaluated with a fluorospectrometer to capture the temporal profiles of fluorescein transport through the np-Au thin film. After 72 h, the PBS condition for all np-Au film types showed noticeable fluorescein transport through the np-Au, while no transport was detected for any of the DI water conditions (**Figure 3**a,b). We attribute this observation to the influence of halides on molecular transport in np-Au thin films.

218

219

220

221

222

223

224

225

226

227

228

229

Specifically, in the absence of halides, fluorescein molecules non-specifically adsorb onto the exposed gold surfaces in the pores via van der Waals interactions and drastically hinder the transport of fluorescein and its release into the sink reservoir. This is in agreement with our findings from fluorescein release experiments from sub-micron-thick np-Au films, where the addition of halides with higher affinity to gold displaced the non-specifically adsorbed fluorescein molecules and resulted in burst release of fluorescein from the thin films [55]. It should be noted that while there was still fluorescein release for the through-thickness transport (sub-micron transport distance) in DI water, the significantly longer transport distance (~1 mm) for in-plane transport essentially ceased any fluorescein release in this study. Unlike for through-thickness release, the coarser films (A-np-Au) did not produce a significant difference in the transport profile in DI water (Figure 3b), suggesting that the increased pore size plays a minor role on fluorescein transport rate over these long distances. Regardless of the film type, the presence of PBS resulted in the sustained fluorescein release into the sink reservoir, as illustrated by the linear cumulative release (Figure 3a). This sustained release is indicative of sustained molecular in-plane transport and is again due to competitive halide adsorption to the gold surface that enhances in-plane transport of fluorescein molecules.




Figure 3. Comparing the in-plane transport through np-Au thin-films under varying conditions. (**a**,**b**) Cumulative release of fluorescein through the np-Au thin-films, indicating a linear increase in cumulative release (indicative of a steady-state transport rate) for all PBS conditions, while minimal transport is observed in DI water (mean \pm SE, n = 4 for all PBS conditions & n = 6 for all DI water conditions). (**c**) Comparing the transport rate of fluorescein through each of the np-Au thin-film types in PBS. Asterisks indicate statistically significant groups (p < 0.05). (**d**) Planar gold (pl-Au) control sample in both DI and PBS conditions did not show any molecular transport (mean \pm SE, n = 3).

To mathematically support the putative underlying adsorption-based mechanism, we utilized the extended Langmuir isotherm model based on each molecular species' magnitude of adsorption [56]. This model can be used to predict the competitive adsorption of multiple species onto a single substrate, and has been used to model adsorption of acidic dyes on activated carbon [57–59]. The pair of equations is given as

$$\theta_{f} = \frac{K_{eq,f}C_{f}}{1 + K_{eq,cl}C_{cl} + K_{eq,f}C_{f}}$$

$$\theta_{cl} = \frac{K_{eq,cl}C_{cl}}{1 + K_{eq,cl}C_{cl} + K_{eq,f}C_{f}}$$
(1)

where θ is the ratio of adsorbed ions and available binding sites, C is the concentration of ions in the pores, and K_{eq} is the Langmuir constant. The concentration of fluorescein ions in the source reservoir was 100 µM. The concentration of chloride ions in PBS is 142 mM. K_{eq} for each fluorescein and chloride ions were calculated as 81.9 mm³ nmol⁻¹ and 3.43 x 10⁵ mm³ nmol⁻¹, respectively (**Figure S1**). Using these values, θ_f and θ_{Cl} were determined to be 1.68 x 10⁻⁷ and nearly 1, respectively. This indicates that in physiological environments (such as in PBS), chlorine ions occupy nearly all available binding sites, thereby limiting fluorescein-gold interaction and permitting relatively unhindered fluorescein transport over large distances (as in the case of in-plane transport).

A comparison of the transport rate in PBS for the three film types reveal the influence of film properties on the in-plane molecular transport (Figure 3c). Linear regression analysis of each film type's cumulative release profiles was used to extract the release rate, which is equivalent to the inplane molecular transport rate. Compared to the release rate for np-Au, the coarser film (A-np-Au) did not lead to a statistically-different release rate (p value = 0.66); however, the film with half the thickness (t-np-Au) resulted in a statistically-significant decrease in the release rate (from 1.98 ± 0.70 ng day⁻¹ to 0.69 ± 0.28 ng day⁻¹; p value = 0.04), as expected from the reduced cross-sectional area for molecular flux. We attribute the slight reduction in A-np-Au's release rate (from 1.98 ± 0.70 ng day⁻¹ to 1.57 ± 0.84 ng day⁻¹) to pore coalescence and shrinkage in film thickness, which effectively reduces the cross-sectional area for molecular flux [43,48]. Steric effects due to narrow pore constrictions were ignored as the hydrodynamic radius of fluorescein (~5 Å) is orders of magnitude smaller than the pore radius of np-Au (20-120 nm) [43,60,61]. To rule out any transport along the interface between the metal and the PDMS manifold, we used planar gold (pl-Au) films as a control for both DI water and PBS environments. For both solutions, negligible molecular release (hence transport) was observed for pl-Au (Figure 3d), confirming that fluorescein transport is primarily occurring through the np-Au thin films in the PBS condition.

In order to verify the relationship between the release rate to transport rate, and to determine the effective diffusion coefficients from experimentally-obtained released rates, we employed Fick's 1st Law for porous media [62,63], which is given by

$$n = \frac{AD_b\varepsilon}{\tau} * \frac{\Delta C}{\Delta x} = AD_e * \frac{\Delta C}{\Delta x}$$
 (2)

where n is molar flux rate (determined in **Figure 3**a), A is the geometric cross-sectional area of the channel (i.e., thin film cross-section), D_{θ} is diffusion coefficient of fluorescein in bulk solution, D_{θ} is effective diffusivity, ε is porosity, τ diffusive tortuosity, C is concentration, and x is length of molecular transport region. It is important to note that the effective diffusivity captures the hinderance of transport through a porous media (compared to an unobstructed channel), yet it does not infer information about the actual diffusivity within interconnected pores (nanochannel). Using righthand side of Equation 2, we extracted the experimental effective diffusivity (D_{θ}) for each film type (**Table 1**). These diffusivities are all below the bulk diffusivity of fluorescein (4.2 x 10⁻⁶ cm² s⁻¹) [64], which would be expected due to hindered transport in a nanoporous film [50]. In tandem, we calculated theoretical effective diffusivities by scaling the previously reported bulk diffusivity of fluorescein (D_{θ})[64] with the porosity and tortuosity values listed in Table 1. The relative errors with respect to the theoretically-determined effectivity diffusivity values are 44%, 55%, and -4% for np-Au, A-np-Au, and t-np-Au respectively. Thicker films have been previous shown to have larger cracks due to relaxation of tensile stress accumulation during dealloying via cracking, which increases the porosity near the surface of the film, and thereby increasing the effective diffusivity [65].

Table 1. Properties for each np-Au film type and the corresponding experimentally- and theoretically-derived effective diffusivities.

Film Type	Porosity, ε	Tortuosity, τ	Exp. Effective Diffusivity [cm ² s ⁻¹]	Theoretical Effective Diffusivity [cm² s-1]	Relative Error w.r.t Theoretical Diffusivity
np-Au	0.55	1.35	2.46 x 10 ⁻⁶	1.71 x 10 ⁻⁶	44%
A-np-Au	0.49	1.42	2.22 x 10 ⁻⁶	1.44 x 10 ⁻⁶	54%
t-np-Au	0.55	1.35	1.65 x 10-6	1.71 x 10-6	-4%

278

279

280

281

282

283

284

285

286

287

288

289

290


291

292

293

294

To further verify our experimental results, we used COMSOL Multiphysics 5.5 package to obtain two-dimensional numerical solutions using the Species Transport in Porous Media module. The geometry was constructed via three tangent rectangles each having a length of 1 mm and height that corresponds to the thickness of each film type (Figure S2a). For simulating the PBS condition, we assumed that fluorescein-gold interactions are negligible due to the dominant halide-gold interactions, and hence did not consider any adsorption term. However, for the DI water condition, the non-specific fluorescein-gold adsorption must be considered; therefore, we used the calculated values for Langmuir isotherm constant ($K_{eq,f}$) and maximum available adsorption sites (Q_{max}) (**Figure** S1). Using additional parameters that were previously discussed such as porosity, tortuosity, and bulk diffusivity, we were able to determine time-dependent concentration profiles across the np-Au thin-film (Figure S2b,c). Comparing DI water and PBS simulation results validates the importance of adsorption on the observed in-plane transport rate through np-Au thin-films. For the PBS case, the transport quickly reaches a steady state (Figure S2b), while for the DI water case, the transport does not reach a steady state even after three days. The calculated cumulative release amounts are approximately within a single standard error of the experimental results (Figure 4), indicating a good agreement between the experimentally- and numerically-obtained transport rates. The simulations underestimate the transport rate for both np-Au and A-np-Au. We attribute this to cracks in the film that may be increasing the transport rate yet that cannot be accurately captured in a simple numerical model.



295296

297

Figure 4. Comparison of the numerical solutions of each film's molecular transport profiles (solid lines) to the experimental values (shaded region representing one standard error from the mean).

3.3. Biofouling Resilience

Biofouling can be a significant impediment to implantable drug delivery systems, especially those with nanostructured delivery components, because the small openings can be blocked by non-specific adsorption of biomolecules such as proteins [66]. Previous studies have shown that np-Au acts as an intrinsic sieve, where partial occlusion of the irregular pores with proteins still allows for small-molecule transport into and out of the nanoporous films [39,67,68]. Here, we assess the molecular release performance of the in-plane transport device in a biofouling condition. Specifically, we filled the *source* and *sink* reservoirs with fluorescein in PBS (Fluo+PBS) and 10% fetal bovine serum (FBS) in PBS (FBS+PBS), respectively. The FBS mimics the rich diversity of proteins in physiological samples. For this study, we only used the np-Au films with the original morphology, as previous studies have shown that np-Au films with larger pores exhibit reduced biofouling resilience, due to increased penetration of biofouling proteins into the pores resulting in higher pore occlusion [39]. We did not observe a statistically-significant difference (*p* value = 0.70) between the release rates for release into the protein-rich solution (FBS+PBS) and the control solution (PBS) (**Figure 5**). This result agrees with previous studies and highlights that small-molecule release can be maintained even biofouling conditions, which is critical for implantable drug delivery platforms.




Figure 5. In-plane molecular transport in biofouling conditions. Both the cumulative release profiles and transport rates (inset) show negligible difference between PBS and serum conditions demonstrating biofouling resistance on np-Au thin-films (mean \pm SE, n = 3).

3.4. Chemical Gating

We have previously discussed the influence of halides on molecular transport in np-Au. Briefly, the PBS (halide presence) enabled in-plane molecular transport while the DI water stopped the transport. Here, we leverage this competitive surface adsorption-mediated phenomenon and investigate its potential for chemical gating of fluorescein release. To that end, we tested two different scenarios, in which the ionic environment was changed either only at the source reservoir (source gating) or only at the sink reservoir (sink gating). Specifically, for source gating, we switched the source reservoir content from Fluo+DI to Fluo+PBS while maintaining the sink with DI water. Conversely, for sink gating, we switched the sink reservoir content from DI water to PBS while maintaining the source with Fluo+DI. For both cases, there was steady-state molecular release when one reservoir contained PBS and there was no release when both reservoirs contained DI water (Figure 6a,c). Additionally, we noted a transient response when switching from DI water to PBS, with an initial

non-linear release profile for 12 hours, followed by a linear profile for the remainder of the PBS incubation. We hypothesize that the non-linear release is due to desorbed fluorescein ions emptying into the sink reservoir following the switch to the PBS environment. After the initial 12 hours, the transport rate reaches a steady state, plausibly due to the molecular adsorption/desorption events resolving. When switching back to DI water condition (DI2), the adsorbed chloride ions diffuse out of the np-Au network due to the large concentration gradient between the np-Au film and reservoirs. Once the np-Au film is devoid of chloride ions, non-specific adsorption of fluorescein onto the gold surfaces resumes, thereby ceasing molecular transport and stopping fluorescein release into the sink. For both gating scenarios, the release rates determined for each cycle (using linear regression) reveal two different clusters (Figure 6b,d) with statistical significance, as determined by a one-way ANOVA/post-hoc Tukey test (p value = 6×10^{-5} for source gating & p value = 1.14×10^{-12} for sink gating). Not only there is a stark difference in the release rate for DI water and PBS conditions, but this difference is highly reproducible across multiple gating cycles. The average release rates for source gating were -0.04 ± 0.07 and 0.86 ± 0.19 ng day⁻¹ for the DI water and PBS conditions, respectively. The average release rates for the sink gating were 0.04 ± 0.03 and 0.66 ± 0.10 ng day⁻¹. For both gating scenarios, where only one reservoir contains PBS at a time, the release rates were expectedly less than the release rate when both reservoirs contained PBS, which was 1.98 ± 0.70 ng day-1 (Figure 3a). These results suggest that the in-plane transport can be gated in response to ionic strength changes in the reservoir content. Put another way, the release rate can be adjusted by modulating the source reservoir contents, which would be located distal to the actual delivery site (sink reservoir). Alternatively, the changes at the site of drug delivery (e.g., tissue), could be used to modulate the release rate. The sensitivity and selectivity of the gold surfaces to the competitive adsorption/desorption (the enabling phenomenon for gated release) can be further tuned by immobilizing functional molecules on the gold surfaces via thiol-gold chemistry, as previously described [42].




Figure 6. Cumulative release profiles and transport rates demonstrating the chemical gating of fluorescein transport via source (\mathbf{a} , \mathbf{b}) and sink (\mathbf{c} , \mathbf{d}) gating. The letters indicate statistically-significant groups (p < 0.05). (mean \pm SE), n = 6 for sink gating & n = 3 for source gating).

357

358

359

4. Conclusions

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

398

399

400

401

402

403

408

409

410

In summary, we studied the influence of ionic environment on in-plane transport of fluorescein ions through np-Au thin films with different morphologies and thicknesses, where the presence of halides enabled molecular transport by reducing non-specific fluorescein (small-molecule drug surrogate) adsorption onto the pore walls. We validated the underlying physics of the in-plane transport and the experimental results with both analytical and numerical (COMSOL Multiphysics® model) methods using an extended Langmuir isotherm model and parameters describing the different np-Au films. The use of the microfluidic device allowed for modeling an anatomical case where the reservoir (source) and the drug delivery site (sink) would be in different locations yet connected with the np-Au thin film for molecular transport. Since np-Au thin films can be patterned via conventional microfabrication techniques, the in-plane transport phenomenon can be translated into multiple electrode arrays [41,69], where np-Au electrode traces can transport small molecules along the traces from the external electrical pads (coupled to individual pharmaceutical reservoirs) to the individual electrode sites for subsequent molecular release. In this scheme, the pharmaceutical dosing can be precisely controlled by voltage-gated release at the electrode sites [70]. We showed that the molecular release rate can also be modulated (gated) by changing the ionic composition/strength at both the source and sink reservoirs, attaining reproducible gated molecule release across several on/off cycles. The device exhibited sustained molecular release in biofouling conditions, where the irregular pore shape and non-unimodal pore size distribution allowed small-molecule transport despite non-specific protein adsorption onto the pore entrances at the source and sink reservoirs. This size exclusion mechanism can find further utility, where np-Au acts as a microbial filter (achieved by 10s nm pore sizes) separating the source and sink reservoirs. This would be highly useful for both in vitro and in vivo cases, where the source reservoir does not need to be kept sterile, while the sink reservoir can remain sterile for cell culture or tissue contact. This would further allow for using the source reservoir for replenishing pharmaceuticals (via several methods involving hypodermic needle-accessible membranes [2,13,71]) without having the remove the implanted devices. In addition, np-Au's antimicrobial properties [72], compatibility with biomolecules and tissue [38], and reproducibility in manufacturing [41] fulfill aspects of the Safe-by-Design approach for nanobiomaterial development, which highlights np-Au's potential for clinical translation [73]. Recent demonstrations of pharmaceutical release from np-Au with biological relevance (e.g., doxorubicin [74], Ara-C [54], and salicylic acid [75]) further support the clinical relevance. Taken together, we expect that the demonstrated phenomenon and the microfluidic model will create new opportunities for biological experiments and fundamental studies of transport phenomena in nanoporous materials.

Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: Properties of np-Au and A-np-Au, Figure S1: Langmuir Constant Calculation, Figure S2: COMSOL Simulation.

Author Contributions: Conceptualization, B.P., N.G., and E.S.; methodology, B.P., N.G., and E.S.; software, B.P. and N.G.; validation, B.P., N.G., and E.S.; formal analysis, B.P., N.G., and E.S.; investigation, B.P. and N.G.; resources, E.S.; data curation, B.P., N.G., and E.S.; writing—original draft preparation, B.P., N.G., and E.S.; writing—review and editing, B.P., N.G., and E.S.; visualization, B.P., N.G., and E.S.; supervision, N.G., and E.S.; project administration, N.G., and E.S.; funding acquisition, E.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by National Science Foundation, grant numbers CBET-1454426 and DMR 2003849, and the National Institutes of Health, grant numbers R21-EB024635, R21-AT010933, and R03-NS118156.
 BP was partially supported by the Provost's Undergraduate Fellowship and the OEOES Fellowship from the University of California, Davis.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

411 References

- 1. Vaccari, L.; Canton, D.; Zaffaroni, N.; Villa, R.; Tormen, M.; di Fabrizio, E. Porous silicon as drug carrier for controlled delivery of doxorubicin anticancer agent. *Microelectron. Eng.* **2006**, *83*, 1598–1601, doi:10.1016/j.mee.2006.01.113.
- 415 2. Gensler, H.; Sheybani, R.; Li, P.; Lo, R.; Zhu, S.; Yong, K.; Prasad, P.N.; Masood, R.; Sinha, U.K.; Meng, E. IMPLANTABLE MEMS DRUG DELIVERY DEVICE FOR CANCER RADIATION REDUCTION. *Drug Deliv.* 2010, 27–30.
- 3. Zhao, L.; Wang, L.; Zhang, Y.; Xiao, S.; Bi, F.; Zhao, J.; Gai, G.; Ding, J. Glucose oxidase-based glucose-sensitive drug delivery for diabetes treatment. *Polymers (Basel)*. **2017**, *9*, 1–21, doi:10.3390/polym9070255.
- 4. Proctor, C.M.; Slézia, A.; Kaszas, A.; Ghestem, A.; del Agua, I.; Pappa, A.M.; Bernard, C.; Williamson, A.; 421 Malliaras, G.G. Electrophoretic drug delivery for seizure control. *Sci. Adv.* 2018, 4, doi:10.1126/sciadv.aau1291.
- 423 5. Sershen, S.; West, J. Implantable, polymeric systems for modulated drug delivery. *Adv. Drug Deliv. Rev.* 424 **2002**, *54*, 1225–1235, doi:10.1016/S0169-409X(02)00090-X.
- 425 6. Kleiner, L.W.; Wright, J.C.; Wang, Y. Evolution of implantable and insertable drug delivery systems. *J. Control. Release* **2014**, *181*, 1–10, doi:10.1016/j.jconrel.2014.02.006.
- 427 7. Razzacki, S.Z.; Thwar, P.K.; Yang, M.; Ugaz, V.M.; Burns, M.A. Integrated microsystems for controlled drug delivery. *Adv. Drug Deliv. Rev.* **2004**, *56*, 185–198, doi:10.1016/j.addr.2003.08.012.
- 429 8. Sonabend, A.M.; Stupp, R. Overcoming the blood-brain barrier with an implantable ultrasound device. 430 Clin. Cancer Res. 2019, 25, 3750–3752, doi:10.1158/1078-0432.CCR-19-0932.
- 9. Pons-Faudoa, F.P.; Ballerini, A.; Sakamoto, J.; Grattoni, A. Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. *Biomed. Microdevices* 2019, 21, doi:10.1007/s10544-019-0389-6.
- 434 10. Dauphin-Ducharme, P.; Yang, K.; Arroyo-Currás, N.; Ploense, K.L.; Zhang, Y.; Gerson, J.; Kurnik, M.; 435 Kippin, T.E.; Stojanovic, M.N.; Plaxco, K.W. Electrochemical Aptamer-Based Sensors for Improved Therapeutic Drug Monitoring and High-Precision, Feedback-Controlled Drug Delivery. *ACS Sensors* 2019, 4, 2832–2837, doi:10.1021/acssensors.9b01616.
- 438 11. Lo, R.; Li, P.Y.; Saati, S.; Agrawal, R.; Humayun, M.S.; Meng, E. A refillable microfabricated drug delivery device for treatment of ocular diseases. *Lab Chip* **2008**, *8*, 1027–1030, doi:10.1039/b804690e.
- 440 12. Li, P.Y.; Shih, J.; Lo, R.; Saati, S.; Agrawal, R.; Humayun, M.S.; Tai, Y.C.; Meng, E. An electrochemical intraocular drug delivery device. *Sensors Actuators, A Phys.* **2008**, 143, 41–48, doi:10.1016/j.sna.2007.06.034.
- 442 13. Forouzandeh, F.; Ahamed, N.N.; Hsu, M.C.; Walton, J.P.; Frisina, R.D.; Borkholder, D.A. A 3D-printed modular microreservoir for drug delivery. *Micromachines* **2020**, *11*, 1–17, doi:10.3390/mi11070648.
- 444 14. Gultepe, E.; Nagesha, D.; Sridhar, S.; Amiji, M. Nanoporous inorganic membranes or coatings for sustained drug delivery in implantable devices. *Adv. Drug Deliv. Rev.* **2010**, *62*, 305–315, doi:10.1016/j.addr.2009.11.003.
- 447 15. Tran, P.A.; Zhang, L.; Webster, T.J. Carbon nanofibers and carbon nanotubes in regenerative medicine. *Adv. Drug Deliv. Rev.* **2009**, *61*, 1097–1114, doi:10.1016/j.addr.2009.07.010.
- 449 16. Bianco, A.; Kostarelos, K.; Prato, M. Applications of carbon nanotubes in drug delivery. *Curr. Opin. Chem.* 450 *Biol.* **2005**, *9*, 674–679, doi:10.1016/j.cbpa.2005.10.005.
- 451 17. Anglin, E.J.; Cheng, L.; Freeman, W.R.; Sailor, M.J. Porous silicon in drug delivery devices and materials. 452 *Adv. Drug Deliv. Rev.* **2008**, *60*, 1266–1277, doi:10.1016/j.addr.2008.03.017.
- 453 18. Pillai, O.; Panchagnula, R. Polymers in Drug Delivery. Curr. Opin. Chem. Biol. 2001, 5, 447–451.
- 454 19. Binauld, S.; Stenzel, M.H. Acid-degradable polymers for drug delivery: A decade of innovation. *Chem.* 455 *Commun.* 2013, 49, 2082–2102, doi:10.1039/c2cc36589h.
- 456 20. Blaszykowski, C.; Sheikh, S.; Thompson, M. Surface chemistry to minimize fouling from blood-based fluids. *Chem. Soc. Rev.* **2012**, 41, 5599–5612, doi:10.1039/c2cs35170f.
- 458 21. Sun, Q.; Yan, F.; Yao, L.; Su, B. Anti-Biofouling Isoporous Silica-Micelle Membrane Enabling Drug Detection in Human Whole Blood. *Anal. Chem.* **2016**, *88*, 8364–8368, doi:10.1021/acs.analchem.6b02091.
- 460 22. Chen, Y.C.; Xie, R.; Chu, L.Y. Stimuli-responsive gating membranes responding to temperature, pH, salt concentration and anion species. *J. Memb. Sci.* **2013**, 442, 206–215, doi:10.1016/j.memsci.2013.04.041.
- 462 23. Aznar, E.; Coll, C.; Dolores Marcos, M.; Artínez-M Áñez, R.M.; Sancenón, F.; Soto, J.; Amorós, P.; Cano, J.; Ruiz, E. Borate-driven gatelike scaffolding using mesoporous materials functionalised with saccharides. *Chem. A Eur. J.* **2009**, *15*, 6877–6888, doi:10.1002/chem.200900090.

- 465 24. Acar, E.T.; Buchsbaum, S.F.; Combs, C.; Fornasiero, F.; Siwy, Z.S. Biomimetic potassium-selective nanopores. **2019**, 1–8.
- 467 25. McCurry, D.A.; Bailey, R.C. Electrolyte Gradient-Based Modulation of Molecular Transport through Nanoporous Gold Membranes. *Langmuir* 2017, 33, 1552–1562, doi:10.1021/acs.langmuir.6b04128.
- 469 26. Brudno, Y.; Silva, E.A.; Kearney, C.J.; Lewin, S.A.; Miller, A.; Martinick, K.D.; Aizenberg, M.; Mooney, D.J. Refilling drug delivery depots through the blood. *Proc. Natl. Acad. Sci. U. S. A.* 2014, 111, 12722–12727, doi:10.1073/pnas.1413027111.
- 472 27. Erlebacher, J.; Aziz, M.J.; Karma, A.; Dimitrov, N.; Sieradzki, K. Evolution of nanoporosity in dealloying. *Nature* **2001**, *410*, 450–453, doi:10.1038/35068529.
- 474 28. Hakamada, M.; Mabuchi, M. Thermal coarsening of nanoporous gold: Melting or recrystallization. *J. Mater.* 475 *Res.* **2009**, 24, 301–304, doi:10.1557/jmr.2009.0037.
- 476 29. Seker, E.; Reed, M.L.; Begley, M.R. Nanoporous gold: Fabrication, characterization, and applications. *Materials (Basel).* **2009**, 2, 2188–2215, doi:10.3390/ma2042188.
- 478 30. Chen-Wiegart, Y.C.K.; Wang, S.; Chu, Y.S.; Liu, W.; McNulty, I.; Voorhees, P.W.; Dunand, D.C. Structural evolution of nanoporous gold during thermal coarsening. *Acta Mater.* **2012**, *60*, 4972–4981, doi:10.1016/j.actamat.2012.05.012.
- 481 31. Dorofeeva, T.S.; Seker, E. Electrically tunable pore morphology in nanoporous gold thin films. *Nano Res.* **2015**, *8*, 2188–2198, doi:10.1007/s12274-015-0726-x.
- 483 32. Sharma, A.; Bhattarai, J.K.; Alla, A.J.; Demchenko, A. V.; Stine, K.J. Electrochemical annealing of nanoporous gold by application of cyclic potential sweeps. *Nanotechnology* **2015**, *26*, doi:10.1088/0957-485 4484/26/8/085602.
- 486 33. Arnob, M.M.P.; Zhao, F.; Zeng, J.; Santos, G.M.; Li, M.; Shih, W.C. Laser rapid thermal annealing enables tunable plasmonics in nanoporous gold nanoparticles. *Nanoscale* **2014**, *6*, 12470–12475, doi:10.1039/c4nr03672g.
- 489 34. Chapman, C.A.R.; Wang, L.; Biener, J.; Seker, E.; Biener, M.M.; Matthews, M.J. Engineering on-chip nanoporous gold material libraries via precision photothermal treatment. *Nanoscale* **2016**, *8*, 785–795, doi:10.1039/c5nr04580k.
- 492 35. Qian, L.H.; Chen, M.W. Ultrafine nanoporous gold by low-temperature dealloying and kinetics of nanopore formation. *Appl. Phys. Lett.* **2007**, *91*, doi:10.1063/1.2773757.
- 494 36. Rouya, E.; Cattarin, S.; Reed, M.L.; Kelly, R.G.; Zangari, G. Electrochemical Characterization of the Surface Area of Nanoporous Gold Films. *J. Electrochem. Soc.* **2012**, *159*, K97–K102, doi:10.1149/2.097204jes.
- 496 37. Xia, R.; Wang, J.L.; Wang, R.; Li, X.; Zhang, X.; Feng, X.Q.; Ding, Y. Correlation of the thermal and electrical conductivities of nanoporous gold. *Nanotechnology* **2010**, *21*, doi:10.1088/0957-4484/21/8/085703.
- 498 38. Seker, E.; Shih, W.C.; Stine, K.J. Nanoporous metals by alloy corrosion: Bioanalytical and biomedical applications. *Physiol. Behav.* **2017**, *176*, 139–148, doi:10.1557/mrs.2017.298.Nanoporous.
- 500 39. Daggumati, P.; Matharu, Z.; Wang, L.; Seker, E. Biofouling-Resilient Nanoporous Gold Electrodes for DNA Sensing. *Anal. Chem.* **2015**, *87*, 8618–8622, doi:10.1021/acs.analchem.5b02969.
- 502 40. Qi, J.; Motwani, P.; Gheewala, M.; Brennan, C.; Wolfe, J.C.; Shih, W.C. Surface-enhanced Raman spectroscopy with monolithic nanoporous gold disk substrates. *Nanoscale* **2013**, *5*, 4105–4109, doi:10.1039/c2nr33242f.
- 505 41. Seker, E.; Berdichevsky, Y.; Begley, M.R.; Reed, M.L.; Staley, K.J.; Yarmush, M.L. The fabrication of low-506 impedance nanoporous gold multiple-electrode arrays for neural electrophysiology studies. 507 *Nanotechnology* **2010**, *21*, doi:10.1088/0957-4484/21/12/125504.
- 508 42. Polat, O.; Seker, E. Effect of Surface-Molecule Interactions on Molecular Loading Capacity of Nanoporous Gold Thin Films. *J. Phys. Chem. C* **2016**, *120*, 19189–19194, doi:10.1021/acs.jpcc.6b05802.
- 510 43. Kurtulus, O.; Daggumati, P.; Seker, E. Molecular release from patterned nanoporous gold thin films. 511 Nanoscale **2014**, *6*, 7062–7071, doi:10.1039/c4nr01288g.
- 512 44. Veselinovic, J.; Almashtoub, S.; Seker, E. Anomalous Trends in Nucleic Acid-Based Electrochemical Biosensors with Nanoporous Gold Electrodes. *Anal. Chem.* **2019**, *91*, 11923–11931, doi:10.1021/acs.analchem.9b02686.
- 515 45. Wittstock, A.; Biener, J.; Bäumer, M. Nanoporous gold: A new material for catalytic and sensor applications. 516 *Phys. Chem. Phys.* **2010**, *12*, 12919–12930, doi:10.1039/c0cp00757a.

- 517 46. Fujita, T.; Guan, P.; McKenna, K.; Lang, X.; Hirata, A.; Zhang, L.; Tokunaga, T.; Arai, S.; Yamamoto, Y.; 518 Tanaka, N.; et al. Atomic origins of the high catalytic activity of nanoporous gold. *Nat. Mater.* **2012**, *11*, 775–780, doi:10.1038/nmat3391.
- 520 47. Daggumati, P.; Kurtulus, O.; Chapman, C.A.R.; Dimlioglu, D.; Seker, E. Microfabrication of nanoporous gold patterns for cell-material interaction studies. *J. Vis. Exp.* **2013**, doi:10.3791/50678.
- 522 48. Seker, E.; Gaskins, J.T.; Bart-Smith, H.; Zhu, J.; Reed, M.L.; Zangari, G.; Kelly, R.; Begley, M.R. The effects of post-fabrication annealing on the mechanical properties of freestanding nanoporous gold structures. *Acta Mater.* **2007**, *55*, 4593–4602, doi:10.1016/j.actamat.2007.03.018.
- 525 49. Kumar, A.; Pillai, J. Implantable drug delivery systems: An overview; Elsevier Inc., 2018; ISBN 9780128136669.
- 526 50. Gultepe, E.; Nagesha, D.; Casse, B.D.F.; Banyal, R.; Fitchorov, T.; Karma, A.; Amiji, M.; Sridhar, S. Sustained drug release from non-eroding nanoporous templates. *Small* **2010**, *6*, 213–216, doi:10.1002/smll.200901736.
- 528 51. Nguyen, Q.H.; Ali, M.; Nasir, S.; Ensinger, W. Transport properties of track-etched membranes having variable effective pore-lengths. *Nanotechnology* **2015**, *26*, doi:10.1088/0957-4484/26/48/485502.
- 530 52. Di Trani, N.; Silvestri, A.; Sizovs, A.; Wang, Y.; Erm, D.R.; Demarchi, D.; Liu, X.; Grattoni, A. Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery. *Lab Chip* **2020**, 20, doi:10.1039/d0lc00121j.
- 533 53. Xue, Y.; Markmann, J.; Duan, H.; Weissmüller, J.; Huber, P. Switchable imbibition in nanoporous gold. *Nat. Commun.* **2014**, *5*, doi:10.1038/ncomms5237.
- 535 54. Seker, E.; Berdichevsky, Y.; Staley, K.J.; Yarmush, M.L. Microfabrication-compatible nanoporous gold foams as biomaterials for drug delivery. *Adv. Healthc. Mater.* **2012**, *1*, 172–176, doi:10.1002/adhm.201200002.
- 537 55. Polat, O.; Seker, E. Halide-Gated Molecular Release from Nanoporous Gold Thin Films. *J. Phys. Chem. C* 2015, 119, 24812–24818, doi:10.1021/acs.jpcc.5b06959.
- 539 56. Butler, J.A.V.; Ockrent, C. Studies in electrocapillarity. Part III: The surface tensions of solutions containing two surface-active solutes. *J. Phys. Chem.* **1930**, *34*, 2841–2859, doi:10.1021/j150318a015.
- 541 57. Choy, K.K.H.; Porter, J.F.; McKay, G. Langmuir isotherm models applied to the multicomponent sorption of acid dyes from effluent onto activated carbon. *J. Chem. Eng. Data* **2000**, *45*, 575–584, doi:10.1021/je9902894.
- 543 58. Terdputtakun, A.; Arqueropanyo, O. anong; Sooksamiti, P.; Janhom, S.; Naksata, W. Adsorption isotherm models and error analysis for single and binary adsorption of Cd(II) and Zn(II) using leonardite as adsorbent. *Environ. Earth Sci.* **2017**, *76*, 1–11, doi:10.1007/s12665-017-7110-y.
- 546 59. Ho, Y.S.; McKay, G. Correlative biosorption equilibria model for a binary batch system. *Chem. Eng. Sci.* **2000**, *55*, 817–825, doi:10.1016/S0009-2509(99)00372-3.
- 548 60. Boving, T.B.; Grathwohl, P. Tracer diffusion coefficients in sedimentary rocks: correlation to porosity and hydraulic conductivity. **2001**.
- 550 61. Chenyakin, Y.; Ullmann, A.D.; Evoy, E.; Renbaum-Wolff, L.; Kamal, S.; Bertram, K.A. Diffusion coefficients of organic molecules in sucrose-water solutions and comparison with Stokes-Einstein predictions. *Atmos. Chem. Phys.* **2017**, *17*, 2423–2435, doi:10.5194/acp-17-2423-2017.
- 553 62. Grathwohl, P. Diffusion in Natural Porous Media: Contaminant Transport, Sorption/Desorption and Dissolution Kinetics; 1998; ISBN 978-1-4615-5683-1.
- 555 63. Rashapov, R.; Imami, F.; Gostick, J.T. A method for measuring in-plane effective diffusivity in thin porous media. *Int. J. Heat Mass Transf.* **2015**, *85*, 367–374, doi:10.1016/j.ijheatmasstransfer.2015.01.101.
- 557 64. Casalini, T.; Salvalaglio, M.; Perale, G.; Masi, M.; Cavallotti, C. Diffusion and aggregation of sodium fluorescein in aqueous solutions. *J. Phys. Chem. B* **2011**, *115*, 12896–12904, doi:10.1021/jp207459k.
- 559 65. Seker, E.; Reed, M.L.; Begley, M.R. A thermal treatment approach to reduce microscale void formation in blanket nanoporous gold films. *Scr. Mater.* **2009**, *60*, 435–438, doi:10.1016/j.scriptamat.2008.11.027.
- 561 66. Adiga, S.P.; Jin, C.; Curtiss, L.A.; Monteiro-Riviere, N.A.; Narayan, R.J. Nanoporous membranes for medical and biological applications. *Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology* **2009**, *1*, 568–581, doi:10.1002/wnan.50.
- 564 67. Saraf, S.; Neal, C.J.; Park, S.; Das, S.; Barkam, S.; Cho, H.J.; Seal, S. Electrochemical study of nanoporous gold revealing anti-biofouling properties. *RSC Adv.* **2015**, *5*, 46501–46508, doi:10.1039/c5ra05043j.
- 566 68. Patel, J.; Radhakrishnan, L.; Zhao, B.; Uppalapati, B.; Daniels, R.C.; Ward, K.R.; Collinson, M.M. Electrochemical properties of nanostructured porous gold electrodes in biofouling solutions. *Anal. Chem.* **2013**, *85*, 11610–11618, doi:10.1021/ac403013r.

- 569 69. Chapman, C.A.R.; Wang, L.; Chen, H.; Garrison, J.; Lein, P.J.; Seker, E. Nanoporous Gold Biointerfaces: 570 Modifying Nanostructure to Control Neural Cell Coverage and Enhance Electrophysiological Recording 571 Performance. *Adv. Funct. Mater.* **2017**, *27*, doi:10.1002/adfm.201604631.
- 572 70. Li, Z.; Polat, O.; Seker, E. Voltage-Gated Closed-Loop Control of Small-Molecule Release from Alumina-573 Coated Nanoporous Gold Thin Film Electrodes. *Adv. Funct. Mater.* **2018**, 28, 1–8, doi:10.1002/adfm.201801292.
- 575 71. Liu, Y.; Song, P.; Liu, J.; Tng, D.J.H.; Hu, R.; Chen, H.; Hu, Y.; Tan, C.H.; Wang, J.; Liu, J.; et al. An in-vivo evaluation of a MEMS drug delivery device using Kunming mice model. *Biomed. Microdevices* **2015**, *17*, doi:10.1007/s10544-014-9917-6.
- 578 72. Hakamada, M.; Taniguchi, S.; Mabuchi, M. Antibacterial activity of nanoporous gold against Escherichia coli and Staphylococcus epidermidis. *J. Mater. Res.* **2017**, *32*, 1787–1795, doi:10.1557/jmr.2017.157.
 - 73. Schmutz, M.; Borges, O.; Jesus, S.; Borchard, G.; Perale, G.; Zinn, M.; Sips, Ä.A.J.A.M.; Soeteman-Hernandez, L.G.; Wick, P.; Som, C. A Methodological Safe-by-Design Approach for the Development of Nanomedicines. *Front. Bioeng. Biotechnol.* **2020**, *8*, 1–7, doi:10.3389/fbioe.2020.00258.
 - 74. Bhattarai, J.K.; Neupane, D.; Nepal, B.; Demchenko, A. V.; Stine, K.J. Nanoporous Gold Monolith for High Loading of Unmodified Doxorubicin and Sustained Co-Release of Doxorubicin-Rapamycin. *Nanomaterials* **2021**, *11*, 208, doi:10.3390/nano11010208.
 - 75. Gittard, S.D.; Pierson, B.E.; Ha, C.M.; Wu, C.A.M.; Narayan, R.J.; Robinson, D.B. Supercapacitive transport of pharmacologic agents using nanoporous gold electrodes. *Biotechnol. J.* **2010**, *5*, 192–200, doi:10.1002/biot.200900250.



© 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

580

581

582

583

584

585

586

587

588